MedCity News

When the Enrollment Freeze Ends, Claim Review Takes Over — Small Providers Need Clear Rules

Woman wearing smart ring on her hand. Concept sport and healthy lifestyle

Beyond Metrics: How to Repair Our Relationship With Wearables

Users are, rightfully, upset that the devices they bought are not delivering the results they were promised. But is that indignation pointed at the right flaw?

By Emma Biggs

BioPharma, Pharma

Drug Approval Marks Another Win for Merck KGaA’s Rare Tumor Strategy

Merck KGaA drug Pimjetmi is now FDA approved for treating tenosynovial giant cell tumor. This drug complements other rare tumor assets the Germany-based drugmaker has acquired in a series of business deals.

By Frank Vinluan

Health Tech

Maven Clinic’s Virtual Care Clinic Goes In Network with 475 Plans

Maven Clinic is making its virtual care services accessible through more than 475 health plans nationwide.

By Marissa Plescia

Latest Video

Latest News

Payers

Democrats’ Midterm Wins Could Reshape Healthcare Access for Underserved Americans

Democrats' huge wins last week might mean big changes coming to healthcare across the country, especially in states which flipped blue. How might the shift in power affect affordability, access, and coverage?

By Jenna Congdon

Can an Infrastructure for Price Transparency Improve Healthcare Competition and Quality?

In an interview, Wayne Luan, senior director, life sciences and provider solutions with Turquoise Health, told MedCity News Editor-in-Chief Arundhati Parmar that the company's platform provides pricing data for medical services, medical devices, and pharmaceutical drugs.

By Stephanie Baum

MedCity Influencers

Follow the Leader: How to Build and Retain Great Clinical Teams

We spend more than a decade training physicians and teach them almost nothing about leading people. So, what do we do? We take the best clinician in the group, hand them the title, and assume that leadership comes with it.

By Sergio Zanotti

Artificial Intelligence, Consumer / Employer

Oura Buys Counsel for $625M, But Will Payers and Consumers Get on Board?

Oura will be integrating Counsel Health's clinical AI and virtual care into its app, but will payers and employers cover the Oura ring as a benefit? And will consumers sign on to pay a much more expensive monthly subscription for AI-enabled medical insights and access to licensed physicians?

By Arundhati Parmar

BioPharma, Pharma

FDA Approves First-in-Class Bayer Drug for Reducing the Risk of Stroke

Bayer’s asundexian, brand name Sunharbo, is the first FDA-approved drug in a new class of cardiovascular medicines. Approval of the once-daily pill covers secondary stroke prevention in adults.

By Frank Vinluan

Artificial Intelligence

An abstract human face dissolves into a cloud of glowing cubes. The image illustrates concepts of data fragmentation, information flow, and technological change on a dark blue background.

New Campaign Wants AI Applications To Look Beyond Speed

Healthcare has plenty of tedious administrative work which could benefit from AI's efficiency - but what if simply speeding up an already broken system isn't the answer? Healthcare leaders push for a re-built, AI-native system in Anterior's recent Beyond Faster Horses campaign.

By Jenna Congdon

MedCity Influencers

The Laboratory Industry’s Next Competitor May Be the Company on Your Patient’s Wrist

The industry’s next major competitor may never build another national laboratory network or employ thousands of phlebotomists. It may simply own the device that notices something first.

By David M. Jackson

Health Tech

Startup Supporting Caregivers Raises $3.5M in Seed Funding

Avanlee Care's seed round was led by BEA Venture Fund, with participation from existing investors, including Board Chair Esther Dyson, Chrysalis Ventures and FairBridge VC.

By Marissa Plescia

BioPharma

Digital Health’s GLP-1 Strategy: “You Didn’t Come for the Drug. You Came for Health”

In a panel discussion, executives from Noom, Omada, Virta and Twin Health discussed how they are going beyond the pill in their GLP-1 strategy and responded to a question about whether they will exist two-to-three years from now.

By Arundhati Parmar

BioPharma, Pharma

Argenx Adds Oral Peptides to Its Immunology Strategy With $550M UNP Acquisition

Argenx’s Unnatural Products acquisition brings a macrocyclic peptides discovery platform for developing oral peptide drugs. The deal brings a new modality to Argenx, whose immunology R&D had focused on antibodies.

By Frank Vinluan

MedCity Influencers

Simulation-Guided Clinical Trials: Is EU Law Ready?

Simulations do not replace human judgment: they inform it, making transparent what would otherwise remain a “black box.” EU law does not require them today; but a proportionate embrace, in the right legislative vehicle, with clear methodological standards, and without crushing noncommercial research, could make trials safer, faster, cheaper, and more reliable, without sacrificing rigor.

By Marco Blei

BioPharma, Pharma

Nkarta Autoimmune Disease Cell Therapy’s First Human Data Show Safety, Signs of Efficacy

Nkarta will present initial clinical data for its natural killer cell therapy in two disorders, myositis and systemic sclerosis, during the American College of Rheumatology annual in Orlando this week. The biotech is part of a growing group of companies developing therapies that reset the immune system to treat autoimmune disease.

By Frank Vinluan

Consumer / Employer

What’s Driving the Consumerization of Healthcare?

Patients increasingly expect convenient, consumer-focused healthcare experiences, panelists said at the recent MedCity INVEST Digital Health Conference.

By Marissa Plescia

MedCity Influencers

Work Safety Concept - regulations and standard in medical hospital. Doctor offers safety first sign on virtual screen

Missing the Point: Isolation Alone Will Not Build AI Safety

Treating AI agents like contract nurses and minimizing their access to critical patient information certainly reduces potential risk. But, it also minimizes key opportunities.

By Gennady Gekht

BioPharma, Pharma

Bispecific J&J Drug Wins Speedy FDA Approval for Treating Head & Neck Cancer

Accelerated FDA approval of Johnson & Johnson’s Rybrevant Faspro covers advanced cases of head and neck cancer. The bispecific antibody was initially approved for treating certain lung cancers.

By Frank Vinluan